Transaction · 0001962926-26-000009

Lin Xichen

Lin Xichen, CSO, reported an open-market or private sale at Structure Therapeutics Inc. involving 1300.000000 shares for an estimated $59623.46. Reported holdings after the transaction were 4639.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SCSO
GPCRStructure Therapeutics Inc.
Trade date
Sep 01, 2026
Filing date
Sep 03, 2026
View on SEC Insider profile
Estimated value-$59.6kShares × reported price
Shares traded1.30k$45.86 per share
Holdings after4.63kDirect
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

GPCR price since this filing

Daily closing prices, with the filing date and available return windows
GPCR · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +1.5%1w ago +5.5%1d ago -3.0%
Returns since7d -16.5%30d -41.6%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
Sell
Code S
Identifier
0001962926-26-000009
American Depositary Shares
Transaction date
Sep 01, 2026
Filed Sep 03, 2026, 01:18 AM · 2d delay
Shares
1,300 sh
$45.86 per share
Estimated value
-$59.6k
Computed from shares × price
Holdings after
4,639 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction Direct Ownership Large Holdings Reduction Large Sale Repeat Seller 10b5-1 Detected
Filing-only score

-16 points

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • timely_filing+4 points

    reporting_delay_days = 2

    Filing reported within two business days of the transaction.
  • derivative_transaction-16 points

    is_derivative = true

    Derivative exercise rows are less discretionary than open-market purchases.
  • tenb5_1_detected-10 points

    is_10b5_1 = true

    Stored filing content includes detected 10b5-1 language.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

CHIEF SCIENTIFIC OFFICER

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    Reflects price per share in Ordinary Shares.

  2. F2

    The Ordinary Shares were converted into American Depositary Shares as reported in Table II.

  3. F3

    1/4 of the Ordinary Shares vested one year after July 22, 2019 (the "Vesting Commencement Date"); the balance of the Ordinary Shares vested in a series of 36 successive equal monthly installments meas…

  4. F4

    This reflects the number of Ordinary Shares remaining under the share option following the partial exercise of the share option for 17,817 Ordinary Shares.

  5. F5

    Each American Depositary Share is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The American Depositary Shares have no expiration date.

  6. F6

    17,817 Ordinary Shares, which were acquired upon exercise of a share option, were converted into 5,939 American Depositary Shares.

  7. F7

    The American Depositary Shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 26, 2026.

  8. F8

    Reflects price per share in American Depositary Shares.

  9. F9

    The weighted average sale price for the transaction reported was $45.8642 and the range of prices were between $45.63 and $46.38. Upon request by the SEC staff, the Issuer, or any security holder of t…

  10. F10

    The weighted average sale price for the transaction reported was $47.2030, and the range of prices were between $46.80 and $47.76. Upon request by the SEC staff, the Issuer, or any security holder of…

Original filing · 0001962926-26-000009
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

GPCR